CSCs participate in cancer immunosurveillance and immune evasion through a variety of mechanisms (Maccalli et al., 2018). Across TCGA cancer types, Thorsson et al. (2018) identified six immune subtypes characterized by differences in macrophage or lymphocyte signatures, Th1:Th2 cell ratio, intratumoral heterogeneity, aneuploidy, the extent of neoantigen load, overall cell proliferation, expression of immunomodulatory genes, and prognosis. Therefore, we investigated ZDHHC5 for its potential association with tumor immunity and possible mechanism. In this study, we analyzed ZDHHC5 expression in immune subtypes and the correlation with the tumor microenvironment of LUAD. The results show that the gene expression of ZDHHC5 distributes evenly among immune subtypes, and we found the expression of ZDHHC5 was not associated with the abundance of immunomodulators and tumor-infiltrating lymphocytes. These results indicated that ZDHHC5 might not be involved in the mechanism of immunotherapy in LUAD.
